Prostate Cancer Update Webcast (2020)

This course will offer a review of what faculty believe are the most important articles in the English-speaking literature on prostate cancer from May 2018 to May 2019. Focus will be placed on articles that have relevance to clinical practice, including both research and clinical articles.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  1. Cite important new publications in this field during the past year.
  2. Identify the relative strengths and weaknesses of the reports.
  3. Appraise how new studies relate to the existing state-of-the-art in clinical practice.
  4. Analyze whether they and their colleagues should consider changing their practice based on the new information.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
08/19/2020
Course expires: 
08/19/2021
Part of: 
Summer School Webcast Series - CME (2020)
Rating: 
0

Education Council Disclosures

PDF icon Education Council Disclosures

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

William Catalona, MD

has a financial relationship (Independent contractor) with Beckman-Coulter Incorporated;.
has a financial relationship (Independent contractor) with Beckman-Coulter Incorporated;.
has a financial relationship (Independent contractor) with Beckman-Coulter Incorporated;.
has a financial relationship (Independent contractor) with deCODE genetics;.
has a financial relationship (Independent contractor) with Beckman-Coulter Incorporated;.
has a financial relationship (Independent contractor) with deCODE genetics;.
Faculty(s)

Douglas Dahl, MD

has a financial relationship (Stock) with Novartis;.
has a financial relationship (Stock) with GlaxoSmithKline;.
has a financial relationship (Stock) with United Medical Systems, Inc.;.
has a financial relationship (Stock) with Mylan;.
has a financial relationship (Stock) with Pfizer;.
has a financial relationship (Stock) with Eli Lilly;.
has a financial relationship (Stock) with Johnson and Johnson;.
has a financial relationship (Stock) with Abbott;.
has a financial relationship (Stock) with Roche;.
has a financial relationship (Stock) with Merck;.
has a financial relationship (Stock) with Amgen;.
has a financial relationship (Stock) with C.R. Bard;.
has a financial relationship (Stock) with Bristol Myers Squibb;.
has a financial relationship (Stock) with Abbvie;.
has a financial relationship (Stock) with ExpressScripts;.
has a financial relationship (Stock) with Eli Lilly;.
has a financial relationship (Stock) with Johnson and Johnson;.
has a financial relationship (Stock) with American Kidney Stone Management;.
has a financial relationship (Stock) with Abbott;.
has a financial relationship (Stock) with Novartis;.
has a financial relationship (Stock) with GlaxoSmithKline;.
has a financial relationship (Stock) with Mylan;.
has a financial relationship (Stock) with Pfizer;.
has a financial relationship (Stock) with Bristol Myers Squibb;.
has a financial relationship (Stock) with Abbvie;.
has a financial relationship (Independent contractor) with Urogen Pharma;.
has a financial relationship (Stock) with ExpressScripts;.
has a financial relationship (Stock) with Roche;.
has a financial relationship (Stock) with Merck;.
has a financial relationship (Stock) with Amgen;.
has a financial relationship (Stock) with C.R. Bard;.

Stanley Liauw,

has a financial relationship (Other) with Nymox ;.
has a financial relationship (Other) with Minomic ;.
has a financial relationship (Independent contractor) with Arivan Research;.
has a financial relationship (Independent contractor) with GenomeDx BIosciences ;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Medivation;.
has a financial relationship (Other) with Hinova;.
has a financial relationship (Independent contractor) with UroGPO;.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Other) with Genetech/Hoffman;.
has a financial relationship (Other) with Myovant ;.
has a financial relationship (Other) with Precision Med;.
has a financial relationship (Other) with Veru Pharmaceuticals;.
has a financial relationship (Other) with FKD;.
has a financial relationship (Independent contractor) with Genomic Health;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Boston Scientific;.
has a financial relationship (Independent contractor) with UROGPO;.
has a financial relationship (Independent contractor) with Vaxiion;.
has a financial relationship (Other) with NeoGenomic Laboratories;.
has a financial relationship (Other) with Cepheid ;.
has a financial relationship (Independent contractor) with 3D Biopsy ;.
has a financial relationship (Independent contractor) with Augmenix ;.
has a financial relationship (Independent contractor) with Myriad Genetics;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with CUSP;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Urogen;.
has a financial relationship (Independent contractor) with Arivan Research;.
has a financial relationship (Other) with Nucleix ;.
has a financial relationship (Independent contractor) with OPKO;.
has a financial relationship (Independent contractor) with Precision Biopsy ;.
has a financial relationship (Other) with BioXcel;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Astra-Zeneca;.
has a financial relationship (Independent contractor) with Swan Valley Medical;.
has a financial relationship (Other) with Siemans;.

Stacy Loeb, MD

has a financial relationship (Other) with Sanofi;.
has a financial relationship (Stock) with Gilead;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Stock) with Gilead;.

Robert Nadler, MD

has a financial relationship (Other) with Retrophin;.
has a financial relationship (Other) with Allena ;.
has a financial relationship (Other) with Retrophin;.
has a financial relationship (Other) with Allena ;.

Russell Szmulewitz,

has a financial relationship (Other) with Genentech;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Genentech;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.50 hours

Release Date: August, 2020
Expiration Date: August, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.